Friday, April 25, 2025 4/25/2025

Anti-inflammatory bioconjugates for sustained inhibition of post-traumatic osteoarthritis following joint injury

Award Number: R43AR074368
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Anti-inflammatory bioconjugates for sustained inhibition of post-traumatic osteoarthritis following joint injury - Project Summary In 2015, an estimated 7.75 million Americans experienced symptoms of osteoarthritis (OA) that could be associated with a known joint injury. Due to a lack of disease modifying therapies, joint replacement surgery is often the only treatment option to eliminate the associated discomfort and restore mobility for patients with post traumatic osteoarthritis (PTOA). Anti-inflammatory therapy has been proposed to inhibit key factors that have a well-known role in mediating joint inflammation and subsequent tissue damage in PTOA. However, due to significant risks that are associated with exposing the patient to anti-inflammatory drugs outside of the target tissue, it is preferable to inject them directly into the affected joint. Unfortunately, currently available drugs for this purpose are rapidly cleared from the joint space, and they need to be re-administered at least weekly to maintain a therapeutic effect. Thus, this potentially disease modifying treatment strategy for PTOA is limited b y the high frequency of drug dosing that would be required. To enable longer-acting drug activity within a specific tissue, we have developed a platform biotechnology for generating clusters of anti-inflammatory drugs to improve their clinical performance. We can control the number of drug repeats in each cluster to engineer their potency and duration of bioactivity. In our preliminary studies, drugs that have been modified using our technology exhibited superior treatment effects to inhibit inflammation compared to equivalent doses of an unmodified version of each drug. We believe a new drug based on our technology will remain within the joint for at least 12 weeks after administration. Therefore, our strategy is well suited to provide long-term inhibition of inflammation in a joint after injury and prevent further inflammation-mediated joint damage. In this project, we will show how increasing the size of our drug clusters will generate sustained treatment effects in the joint space to inhibit injury-induced inflammation and prevent further damage from accumulating in the joint. As a part of this project, we will measure the amount of time that our drug remains in the joint compared to currently available products. We will also verify that a longer residence time in the joint will be sufficient to prevent the development of PTOA using a preclinical model. This project will demonstrate proof-of-concept for our technology to provide sustained anti-inflammatory therapy in a joint after injury.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2018	VALITOR, INC.	2956 SAN PABLO AVE	BERKELEY	CA	94702	ALAMEDA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	11/23/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = -$252 )
2022	2018	VALITOR, INC.	2956 SAN PABLO AVE	BERKELEY	CA	94702	ALAMEDA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	10/23/2021	NEW	-$252
														Subtotal = -$252

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2018	VALITOR, INC.	820 HEINZ AVE	BERKELEY	CA	94710	ALAMEDA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	7/28/2020	NEW	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $224,838 )
2018	2018	VALITOR, INC.	820 HEINZ AVE	BERKELEY	CA	94710	ALAMEDA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	9/11/2018	NEW	$224,838
														Subtotal = $224,838

Grand Total All Awards = $224,586

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Anti-inflammatory bioconjugates for sustained inhibition of post-traumatic osteoarthritis following joint injury

Award Number: R43AR074368

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer